Vaxcyte subsidiary signs commercial manufacturing deal with Lonza for pneumococcal vaccine

Vaxcyte, Inc.

Lonza will build a dedicated suite in Visp, Switzerland to manufacture drug substance for Vaxcyte's pneumococcal conjugate vaccine franchise.
Vaxcyte GmbH pays CHF 27M repurposing fee within 30 days, credited over 10 years from commercial production start.
Agreement term through Dec 31, 2038, renewable for three 5-year periods; termination penalty up to CHF 70M under certain conditions.
Vaxcyte retains right to use alternate manufacturers; receives perpetual, royalty-free license to Lonza's IP for the Products.
Pre-commercial service fees and capital expenditure contributions commence before suite certification for commercial operation.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vaxcyte, Inc. entered into Commercial Manufacturing and Supply Agreement with Lonza Ltd (effective 2023-10-13).

Action: entry
Agreement: supply
Counterparty: Lonza Ltd
Effective: 2023-10-13

Exact text from the filing

On October 13, 2023 (the “Effective Date”), Vaxcyte Switzerland GmbH (“Vaxcyte GmbH”), a Swiss limited liability company that, as of such date, was in the process of being formed by Vaxcyte, Inc. (“Vaxcyte”) (as a wholly-owned subsidiary of Vaxcyte), entered into a pre-commercial services and commercial manufacturing supply agreement (the “Commercial Manufacturing and Supply Agreement”) with Lonza Ltd (“Lonza”).

View on SEC.gov

Browse all material agreements →

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-256533

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.